PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsUpadacitinib
Rinvoq(upadacitinib)
Rinvoq (upadacitinib) is a small molecule pharmaceutical. Upadacitinib was first approved as Rinvoq on 2019-08-16. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1. In addition, it is known to target tyrosine-protein kinase JAK3, tyrosine-protein kinase JAK2, and non-receptor tyrosine-protein kinase TYK2.
Download report
Favorite
FDA Novel Drug Approvals 2019
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Rinvoq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Upadacitinib
Tradename
Company
Number
Date
Products
RINVOQAbbVieN-211675 RX2019-08-16
3 products, RLD
RINVOQ LQAbbVieN-218347 RX2024-04-26
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
rinvoqNew Drug Application2026-06-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
Expiration
Code
UPADACITINIB, RINVOQ, ABBVIE
2026-05-18I-919
2025-04-29I-888
2025-03-16I-886
2025-01-14I-883
2024-12-14I-880
2024-08-16NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Upadacitinib, Rinvoq, Abbvie
115649222038-03-09U-3624
116074112038-03-09U-3341
99510802036-10-17DS, DP
99634592036-10-17DP
102023932036-10-17DP
103440362036-10-17DP
105191642036-10-17DP
105501262036-10-17U-3298
105974002036-10-17U-3255
107308832036-10-17DP
109819232036-10-17DP
109819242036-10-17DP
109950952036-10-17U-3298
111865842036-10-17DP
111986972036-10-17DP
113651982036-10-17U-3275
115120922036-10-17U-3275, U-3371, U-3487
115249642036-10-17U-3371
115356242036-10-17U-3255
115356252036-10-17U-3298
115356262036-10-17U-3298
116614252036-10-17DS, DP
116800692036-10-17DS, DP
117186272036-10-17DS, DP
117673262036-10-17U-3298
117731052036-10-17DS, DP
117731062036-10-17U-3275, U-3371, U-3487
117808472036-10-17DP
117808482036-10-17U-3371
117878152036-10-17DP
117951752036-10-17U-3255
89626292031-01-15DPU-3255, U-3275, U-3341, U-3371, U-3624
RE472212030-12-01DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA44: Upadacitinib
HCPCS
No data
Clinical
Clinical Trials
180 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.9171351540
Atopic dermatitisD003876EFO_0000274L20121232240
ArthritisD001168EFO_0005856M05-M14161211029
Ulcerative colitisD003093EFO_0000729K51—1651526
Crohn diseaseD003424EFO_0000384K5012521525
DermatitisD003872—L30.91162717
EczemaD004485—L30.91162717
Psoriatic arthritisD015535EFO_0003778L40.5—1221015
SpondylarthritisD025241———21249
PsoriasisD011565EFO_0000676L40——2136
Show 7 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ankylosing spondylitisD013167EFO_0003898M45—21—36
ColitisD003092EFO_0003872K52.9—14—26
UlcerD014456MPATH_579——14—26
Systemic lupus erythematosusD008180EFO_0002690M32—31—15
Hidradenitis suppurativaD017497—L73.2—21—25
Alopecia areataD000506EFO_0004192L63——3—25
Joint diseasesD007592—M12.9——4——4
Musculoskeletal diseasesD009140————4——4
Giant cell arteritisD013700EFO_1001209M31.6—11—24
Juvenile arthritisD001171EFO_1002007M08111——3
Show 8 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PruritusD011537—L29—1——23
Digestive system diseasesD004066EFO_0000405K92.9—1——12
HidradenitisD016575———1———1
Sjogren's syndromeD012859EFO_0000699M35.0—1———1
SyndromeD013577———1———1
Relapsing polychondritisD011081EFO_1001148M94.111———1
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3—1———1
ThrombocytopeniaD013921HP_0001873D69.6—1———1
Behcet syndromeD001528EFO_0003780M35.2—1———1
DermatomyositisD003882EFO_0000398M33—1———1
Show 12 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2———13
PharmacokineticsD010599——1————1
Rectal fistulaD012003—K60.31————1
FistulaD005402——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Inflammatory bowel diseasesD015212EFO_0003767—————88
Intestinal diseasesD007410—K63.9————33
InflammationD007249MP_0001845—————22
Drug-related side effects and adverse reactionsD064420—T88.7————11
Recreational drug useD000084783——————11
AlopeciaD000505—L64————11
Gastrointestinal diseasesD005767——————11
NeoplasmsD009369—C80————11
Mycosis fungoidesD009182—C84.0————11
T-cell lymphoma cutaneousD016410—C84.A————11
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameUpadacitinib
INNupadacitinib
Description
Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.
Classification
Small molecule
Drug classtyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Identifiers
PDB—
CAS-ID1310726-59-0
RxCUI—
ChEMBL IDCHEMBL3622821
ChEBI ID—
PubChem CID58557659
DrugBankDB15091
UNII ID4RA0KN46E0 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TYK2
TYK2
Organism
Homo sapiens
Gene name
TYK2
Gene synonyms
NCBI Gene ID
7297
Protein name
non-receptor tyrosine-protein kinase TYK2
Protein synonyms
Uniprot ID
Q96CH0
Mouse ortholog
Tyk2 (54721)
non-receptor tyrosine-protein kinase TYK2 (Q9R117)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Rinvoq – AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 6,818 documents
View more details
Safety
Black-box Warning
Black-box warning for: Rinvoq
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
80,052 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use